Perpetual Medicines has built an integrated platform that combines physics-based computational methods, next-generation AI, and advanced synthetic chemistry to explore vast peptide chemical space and predict binding and drug-like properties. The platform virtually iterates through millions of peptide sequences and integrates computational predictions with experimental data to discover and optimize product candidates. With the new financing the company plans to advance its lead program to the clinical stage and continue building a preclinical portfolio across oncology, autoimmunity, and metabolic diseases. Perpetual positions peptide therapeutics as a rapidly growing sector that can address targets between small molecules and antibodies, enabling access to previously undruggable biology. The company has operations in Shanghai and Boston and has assembled a senior management team with more than 120 years of combined drug discovery experience and involvement in over ten marketed peptide therapeutics. It closed an $8 million seed financing led by Chengwei Capital to advance its platform and programs.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2023